Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipa

$JADE Rises: Jade Biosciences to Release JADE101 Phase 1 Interim Data in Q2 2026, Phase 2 Trials to Follow
Jade Biosciences to report JADE101 interim data in Q2 2026, starts Phase 2 trials mid-2026
#BiotechNews #JadeBiosciences #InvestInHealthcare

https://a777.lt/XhSo5V